Amgen Return on Equity (ROE) Growth & History (AMGN)
Amgen's return on equity was 106.10% for fiscal 2025.
View full Amgen company overviewAmgen annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 106.10% | +38.55 pp |
| 2024 | 2024-12-31 | 67.55% | −68.24 pp |
| 2023 | 2023-12-31 | 135.79% | +9.32 pp |
| 2022 | 2022-12-31 | 126.47% | +53.31 pp |
| 2021 | 2021-12-31 | 73.16% | −2.97 pp |
| 2020 | 2020-12-31 | 76.13% | +5.40 pp |
| 2019 | 2019-12-31 | 70.73% | +26.25 pp |
| 2018 | 2018-12-31 | 44.48% | +37.30 pp |
| 2017 | 2017-12-31 | 7.18% | −19.47 pp |
| 2016 | 2016-12-31 | 26.65% | +0.88 pp |
| 2015 | 2015-12-31 | 25.77% | +4.22 pp |
| 2014 | 2014-12-31 | 21.55% | −3.14 pp |
| 2013 | 2013-12-31 | 24.69% | +1.88 pp |
| 2012 | 2012-12-31 | 22.81% | +5.67 pp |
| 2011 | 2011-12-31 | 17.14% | −2.71 pp |
| 2010 | 2010-12-31 | 19.85% | −1.29 pp |
| 2009 | 2009-12-31 | 21.15% | +0.58 pp |
| 2008 | 2008-12-31 | 20.57% | — |
Amgen quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 22.75% | +1.75 pp |
| Q1 2026 | 2026-03-31 | 20.38% | −8.25 pp |
| Q4 2025 | 2025-12-31 | 14.59% | +5.23 pp |
| Q3 2025 | 2025-09-30 | 37.73% | −4.34 pp |
| Q2 2025 | 2025-06-30 | 21.00% | +7.38 pp |
| Q1 2025 | 2025-03-31 | 28.63% | +30.64 pp |
| Q4 2024 | 2024-12-31 | 9.36% | −1.69 pp |
| Q3 2024 | 2024-09-30 | 42.08% | +18.11 pp |
| Q2 2024 | 2024-06-30 | 13.63% | −9.11 pp |
| Q1 2024 | 2024-03-31 | −2.01% | −65.08 pp |
| Q4 2023 | 2023-12-31 | 11.05% | −33.14 pp |
| Q3 2023 | 2023-09-30 | 23.97% | −46.62 pp |
| Q2 2023 | 2023-06-30 | 22.74% | −56.24 pp |
| Q1 2023 | 2023-03-31 | 63.07% | +24.31 pp |
| Q4 2022 | 2022-12-31 | 44.19% | +18.73 pp |
| Q3 2022 | 2022-09-30 | 70.59% | +49.12 pp |
| Q2 2022 | 2022-06-30 | 78.98% | — |
| Q1 2022 | 2022-03-31 | 38.76% | +21.20 pp |
| Q4 2021 | 2021-12-31 | 25.46% | +9.60 pp |
| Q3 2021 | 2021-09-30 | 21.47% | +2.77 pp |
| Q1 2021 | 2021-03-31 | 17.56% | −1.49 pp |
| Q4 2020 | 2020-12-31 | 15.86% | −0.78 pp |
| Q3 2020 | 2020-09-30 | 18.70% | — |
| Q2 2020 | 2020-06-30 | 17.90% | −2.25 pp |
| Q1 2020 | 2020-03-31 | 19.05% | +1.98 pp |
| Q4 2019 | 2019-12-31 | 16.64% | +2.28 pp |
| Q2 2019 | 2019-06-30 | 20.15% | +5.11 pp |
| Q1 2019 | 2019-03-31 | 17.08% | +5.76 pp |
| Q4 2018 | 2018-12-31 | 14.36% | +29.20 pp |
| Q3 2018 | 2018-09-30 | 12.71% | +6.39 pp |
| Q2 2018 | 2018-06-30 | 15.04% | +8.14 pp |
| Q1 2018 | 2018-03-31 | 11.31% | +4.47 pp |
| Q4 2017 | 2017-12-31 | −14.84% | −21.22 pp |
| Q3 2017 | 2017-09-30 | 6.32% | −0.30 pp |
| Q2 2017 | 2017-06-30 | 6.90% | +0.54 pp |
| Q1 2017 | 2017-03-31 | 6.84% | +0.15 pp |
| Q4 2016 | 2016-12-31 | 6.38% | −0.04 pp |
| Q3 2016 | 2016-09-30 | 6.62% | −0.10 pp |
| Q2 2016 | 2016-06-30 | 6.36% | +0.24 pp |
| Q1 2016 | 2016-03-31 | 6.69% | +0.49 pp |
| Q4 2015 | 2015-12-31 | 6.42% | +1.36 pp |
| Q3 2015 | 2015-09-30 | 6.72% | +1.71 pp |
| Q2 2015 | 2015-06-30 | 6.12% | −0.44 pp |
| Q1 2015 | 2015-03-31 | 6.21% | +1.42 pp |
| Q4 2014 | 2014-12-31 | 5.06% | +0.40 pp |
| Q3 2014 | 2014-09-30 | 5.01% | −1.63 pp |
| Q2 2014 | 2014-06-30 | 6.57% | — |
| Q1 2014 | 2014-03-31 | 4.79% | −2.65 pp |
| Q4 2013 | 2013-12-31 | 4.66% | +0.52 pp |
| Q3 2013 | 2013-09-30 | 6.64% | — |
| Q1 2013 | 2013-03-31 | 7.44% | — |
| Q4 2012 | 2012-12-31 | 4.14% | −0.11 pp |
| Q4 2011 | 2011-12-31 | 4.24% | −0.01 pp |
| Q1 2011 | 2011-03-31 | 4.60% | −0.59 pp |
| Q4 2010 | 2010-12-31 | 4.26% | +0.17 pp |
| Q3 2010 | 2010-09-30 | 5.23% | −1.04 pp |
| Q2 2010 | 2010-06-30 | 5.28% | −0.73 pp |
| Q1 2010 | 2010-03-31 | 5.19% | — |
| Q4 2009 | 2009-12-31 | 4.09% | — |
| Q3 2009 | 2009-09-30 | 6.27% | — |
| Q2 2009 | 2009-06-30 | 6.01% | — |
Amgen return on equity trends
Over the last five fiscal years, Amgen's return on equity increased from 76.13% to 106.10%, a change of +29.97 percentage points. The latest reported quarter, Q2 2026, shows 22.75%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗